Carolyn Cross Purchases 149,225 Shares of Ondine Biomedical Inc. (LON:OBI) Stock

Ondine Biomedical Inc. (LON:OBI) insider Carolyn Cross purchased 149,225 shares of the company’s stock in a transaction dated Monday, February 3rd. The stock was bought at an average cost of C$13.00 per share, for a total transaction of C$1,939,925.00.

Carolyn Cross also recently made the following trade(s):

• On Thursday, January 30th, Carolyn Cross acquired 200,775 shares of Ondine Biomedical stock. The shares were purchased at an average cost of C$12.00 per share, with a total value of C$2,409,300.00.

Ondine Biomedical Stock Performance

Shares of OBI stock opened at C$12.25 on Thursday. The firm has a market cap of C$3.40 billion, a P/E ratio of -408.33 and a beta of 0.10. The company has a debt-to-equity ratio of 1,847.37, a current ratio of 0.80 and a quick ratio of 8.26. Ondine Biomedical Inc. has a fifty-two week low of C$4.50 and a fifty-two week high of C$13.30. The stock’s 50-day moving average is C$9.43 and its two-hundred day moving average is C$8.07.

About Ondine Biomedical

Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens.

Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings.